Replies to post #18536 on Aytu BioScience Inc. (AYTU)

[Drugdoctor]

No, they raised the cash by selling shares.... don't see em using it to buy back shares, even though they would be buying them much cheaper than they sold them... I think by buying out another company with a combination of cash and shares, that is already NET PROFITABLE, would be a better use of the cash... However, if the revenues continue to grow, as they did the previous quarter, they likely will be cash flow positive by the end of March 2021, imo... They could achieve cash flow positive this year, if they are successfully marketing the COV19 tests they have.

Here's another tidbit I saw in the financials...

Accounts receivable, net
6,111,911
Inventory, net
11,479,557

They have a huge inventory.... If they sell it.... and if they collect on those accounts receivable... that will be a huge boost to the balance sheet!

[BottomBounce]

$AYTU The COVID-19 IgG/IgM (Whole Blood/Serum/Plasma) Rapid Test is a lateral flow immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood, plasma from anticoagulated blood (Li+ heparin, K2EDTA and sodium citrate), or serum. The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) should not be used to diagnose acute SARS-CoV-2 infection.